|
|
|
| Randomized trial of oxycodone hydrochloride prolonged-release tablets with or without amitriptyline for severe cancer pain patients with depression |
| WANG Jiangang |
Department of Liver Disease, the Sixth People’s Hospital of ShaoXing, ShaoXing, 312000
|
|
| Cite this article: |
|
WANG Jiangang. Randomized trial of oxycodone hydrochloride prolonged-release tablets with or without amitriptyline for severe cancer pain patients with depression[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(3): 215-217.
|
|
|
Abstract Objective: To investigate the clinical efficacy of oxycodone hydrochloride prolonged-release tablets with or without amitriptyline for severe cancer pain patients with depression. Methods: Thirty-four patients with severe cancer pain and depression were randomly divided into two groups. Oxycodone hydrochloride sustained-release tablets combined with amitriptyline were applied for 17 patients in treating group. Oxycodone hydrochloride sustained-release tablets without amitriptyline for cancer pain treatment as control group. All patients were observed for a period of four weeks. The facial pain rating scale (FPS-R) and Hamilton rating scale for depression (HAMD17) were used to assess the clinical efficacy. The dose and adverse drug reactions of Oxycodone were recorded. Results: Pain relieved in each groups of the patients after treatment (P<0.01). It was more effective that depression improved in treating group, HAMD17 scores were significantly lower than that of pretreatment and the control group (P<0.01). The average daily dosage of oxycodone hydrochloride prolonged-release tablets for treating group was significantly lower than that for the control group during the fourth week (P<0.01) and the adverse reactions between two groups have no significant difference. Conclusion: Oxycodone hydrochloride prolonged-release tablets combined amitriptyline can effectively control severe cancer pain, improve depressive symptoms and quality of life for advanced cancer patients.
|
|
Received: 27 April 2015
|
| |
|
|
|
[1] BRINTZENHOFE-SZOC K M, LEVIN T T, LI Y, et al. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type[J]. Psychosomatics, 2009, 50(4): 383-391.
[2] SMITH H R. Depressionin cancer patients: Pathogenesis, implications and treatment[J]. Oncol Lett, 2015, 9(4): 1509-1514.
[3] PINQUART M, DUBERSTEIN P R. Depression and cancer mortality: a meta-analysis[J]. Psychol Med, 2010, 40: 1797-1810.
[4] 中华人民共和国卫生部. 癌症疼痛诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2012, 17(2): 153-158.
[5] 孙燕, 石远凯. 临床肿瘤内科手册[M]. 北京: 人民卫生出版社, 2007: 257-264.
[6] RILEY J, BRANFORD R, DRONEY J, et al. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial[J]. J Pain Symptom Manage, 2015, 49 (2): 161-172.
[7] 侯培锋, 林小燕, 陈强. 盐酸羟考酮控释片治疗晚期癌症疼痛的临床疗效及安全性分析[J]. 中国医院药学杂志,2015, 35(4): 329-332.
[8] LAIRD B, COLVIN L, FALLON M. Management of cancer pain: basic principles and neuropathic cancer pain[J]. Eur J Cancer, 2008, 44(8): 1078-1082. |
|
|
|
